"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

NARecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Renal Cell Carcinoma (RCC)
Interventions
PROCEDURE

Trans-arterial embolization (TAE)

Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.

Trial Locations (4)

19107

RECRUITING

Thomas Jefferson Health, Philadelphia

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

55905

RECRUITING

Mayo Clinic, Rochester

94305

RECRUITING

Stanford Cancer Institute, Stanford

All Listed Sponsors
collaborator

Varian, a Siemens Healthineers Company

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT05410509 - "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)" | Biotech Hunter | Biotech Hunter